The new sequencing technologies also hold the promise to give valuable data for prognosis determination of CLL patients, most notably TP53, NOTCH1, ATM, SF3B1 and BIRC3 mutations [42] [43]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.